Takeda Shares Slip After Entyvio Posts 47.3% Week-54 Remission Rate
Takeda’s Phase 3 KEPLER trial of Entyvio in 2-17-year-old ulcerative colitis patients achieved a 47.3% remission rate at week 54 and 34.7% at week 14. Shares fell 0.64% to $18.55 despite trading 1.5% above its 20-day SMA and 3.2% above its 100-day SMA as bearish MACD offsets neutral RSI.
1. KEPLER Trial Efficacy Results
The Phase 3 KEPLER trial of Entyvio in children aged two to 17 with moderately to severely active ulcerative colitis showed a 47.3% clinical remission rate at week 54, 34.7% at week 14 and a sustained remission rate of 29% at both assessments, highlighting significant pediatric efficacy.
2. Stock Reaction to Trial News
Takeda shares fell 0.64% to $18.55 following the trial announcement, underperforming the broader health care sector’s modest gains; this reaction reflects short-term investor caution despite positive clinical outcomes.
3. Technical Trend Signals
The stock trades 1.5% above its 20-day SMA and 3.2% above its 100-day SMA, indicating short-term strength, while a neutral RSI of 50 and a bearish MACD reading point to mixed momentum; key support sits at $18 and resistance at $19.